News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone


8/8/2012 10:28:47 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technologyâ„¢ and Dicer Substrate siRNA (DsiRNA) molecules, announced today that Kyowa Hakko Kirin Co., Ltd. (TSE: 4151) (KHK) has recognized the successful achievement of an in vivo activity milestone in the development of its second collaborative therapeutic oncology candidate. This achievement triggers an undisclosed milestone payment to Dicerna.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES